Xin Lang Cai Jing·2025-09-16 11:57Core Points - The article discusses the latest developments in a lawsuit involving Jibeier and Hubei Jiuzhoutong Pharmaceutical Co., Ltd. regarding a contract dispute over the promotion of the drug Nigulol tablets [1][2] - The lawsuit has undergone multiple legal proceedings, with Jiuzhoutong as the plaintiff and Jibeier as the defendant in the main case, while Jibeier has counterclaimed [1] - The amounts involved in the case include 99.08262 million yuan for the main case and 6 million yuan for the counterclaim, with 60 million yuan involved in the appeal and retrial stages [1] Legal Proceedings Summary - First Instance: The Wuhan Intermediate People's Court issued a civil judgment in 2021 [2] - Second Instance: Jiuzhoutong appealed the first-instance judgment, leading to a civil judgment by the Hubei High People's Court in 2022 [2] - Retrial: Jiuzhoutong's application for retrial was rejected by the Supreme People's Court in 2023 [2] - Supervision Application: Jiuzhoutong's request for supervisory review was not supported by the Hubei Provincial People's Procuratorate, indicating that the previous judgment did not meet the conditions for supervision [2] Financial Impact - As of the announcement date, the comprehensive results of the various stages of judgment and decisions suggest that the case is not expected to have a significant impact on Jibeier's financial status and operational results for the current and future periods [2]